Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).


Recent & Breaking News (OTCPK:TSOI)

Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection

Business Wire 3 days ago

Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial

Business Wire September 20, 2022

Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder

Business Wire September 19, 2022

Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)

Business Wire September 12, 2022

Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome

Business Wire August 29, 2022

Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome

Business Wire August 25, 2022

Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte(TM) on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches

Business Wire August 12, 2022

Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells

Business Wire July 28, 2022

Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell(TM) Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial

Business Wire July 18, 2022

John Hopkin's University Publishes Efficacy of QuadraMune(TM) Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

Business Wire May 27, 2022

Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board

Business Wire May 25, 2022

Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial

Business Wire May 23, 2022

Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell(TM) for Treatment of COPD

Business Wire May 12, 2022

Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell(TM) Universal Donor Adult Stem Cells

Business Wire May 9, 2022

Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell(TM) Universal Donor Stem Cell Drug

Business Wire May 2, 2022

Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell(TM) to Stimulate Healing of Injured Lung Tissue

Business Wire April 19, 2022

Therapeutic Solutions International Provides Correction Re Prior Release

Business Wire March 30, 2022

Therapeutic Solutions International Selects Premier Regenerative Medicine CRO Biorasi to Initiate and Run Phase III FDA Registration Clinical Trial for JadiCell(TM) Universal Donor Adult Stem Cell Product

Business Wire March 28, 2022

Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami

Business Wire March 25, 2022

Therapeutic Solutions International Granted Second United States Patent on QuadraMune® for Prevention, Inhibition, and Treatment of COVID-19

Business Wire March 10, 2022